Dermatology Life Quality Index
Also known as: DLQI, Finlay Index, Dermatology Quality of Life
The DLQI is the primary patient-centered outcome measure in dermatology research and clinical practice. Developed by Andrew Finlay and Gul Khan in 1994, this 10-item self-report questionnaire quantifies the impact of skin disease on patients' daily functioning, emotional well-being, social relationships, and work capacity. It is simple, rapid, and applicable to virtually all dermatological conditions, making it the gold standard for assessing quality of life in dermatology.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
The DLQI is indicated in any dermatology clinical or research setting where patient quality of life is relevant. This includes assessing impact at baseline to guide treatment planning, monitoring response to therapy (improvement in quality of life alongside or sometimes preceding clinical improvement), comparing treatment options, evaluating new drugs in trials, audit and quality improvement in dermatology services, and examining long-term consequences of chronic skin disease. It is appropriate for all skin conditions (eczema, psoriasis, acne, vitiligo, alopecia, rosacea, etc.). It is not appropriate for non-dermatological conditions, though skin manifestations of systemic disease (e.g., lupus) can be assessed.
Strengths & limitations
- Brevity and feasibility—10 items, 1-2 minute completion time, compatible with routine clinical practice without imposing burden on patients or clinicians
- Strong validity—extensively validated across 80+ languages and dermatological conditions, showing good discriminant validity between disease severities and responsiveness to treatment
- Patient-centered—developed directly from patient interviews and priorities, measuring outcomes patients care about
- Internationally standardized—DLQI guidelines ensure consistent administration and interpretation worldwide; endorsed by major dermatology societies
- Free to use—unrestricted access for clinical and research use; no copyright restrictions limiting adoption
- Weak disease-severity correlation—demonstrates that quality of life is independent of objective clinical measures, justifying its use as a co-primary endpoint in trials
- Limited symptom depth—does not assess specific symptoms (itch, pain, weeping) in detail; if symptom characterization is needed, disease-specific symptom scales must be added
- No diagnostic capability—measures impact but does not diagnose skin disease or comorbidities (depression, anxiety); supplementary instruments necessary for diagnosis
- Score interpretation depends on disease context—the clinical meaning of a DLQI of 8 differs for acute contact dermatitis (expected short-term) versus severe psoriasis (chronic); reference values and disease-specific norms aid interpretation
- Assumes stable conditions—designed for conditions with relatively stable manifestations; rapidly fluctuating acute conditions may generate variable scores unrelated to true quality-of-life change
- Not validated in children <16 years—use Children's DLQI (cDLQI) for younger patients; DLQI responses may not reliably reflect quality of life in very young children
Frequently asked
How is DLQI interpreted for acute versus chronic skin disease?
For acute conditions (e.g., contact dermatitis, acute urticaria), DLQI quantifies temporary disruption; a DLQI of 12 might be clinically acceptable if expected to resolve in days to weeks. For chronic conditions (e.g., psoriasis, atopic dermatitis), the same DLQI of 12 represents ongoing burden and typically warrants aggressive treatment. Always consider disease duration when interpreting DLQI scores.
Does DLQI score correlate with clinical severity (e.g., PASI for psoriasis)?
Correlation is weak to modest (typically r = 0.30-0.50). Many patients with extensive disease report low DLQI (good coping, mild psychological impact), while others with limited disease report high DLQI (severe cosmetic or itch distress). This independence justifies using DLQI as a separate outcome measure alongside clinical severity.
What constitutes a clinically significant DLQI change during treatment?
A change of ≥4 points is considered clinically meaningful. Improvement from DLQI 15 to 11 represents meaningful benefit. The magnitude of meaningful change may vary by baseline severity and condition; disease-specific studies sometimes define context-specific minimally important differences.
Is DLQI suitable for assessing systemic diseases with skin manifestations?
DLQI can quantify life impact from skin symptoms in systemic diseases (e.g., lupus cutaneous manifestations, scleroderma-associated skin tightness), but it does not measure systemic disease burden. Combine DLQI with systemic disease-specific measures (e.g., SLE disease activity index) for comprehensive assessment.
Sources
- Finlay, A. Y., & Khan, G. K. (1994). Dermatology Life Quality Index (DLQI): A simple practical measure for routine clinical use. Clinical and Experimental Dermatology, 19(3), 210-216. DOI: 10.1111/j.1365-2230.1994.tb01167.x ↗
- Hongbo, Y., Thomas, C. L., Harrison, M. A., Salek, M. S., & Finlay, A. Y. (2005). Translating the science of quality of life into practice: What do dermatology patients' need? Dermatologic Clinics, 23(4), 675-684. link ↗
- Basra, M. K., Fenech, R., Gatt, R. M., Salek, M. S., & Finlay, A. Y. (2008). The Dermatology Life Quality Index 1994-2007: A review of instrument evolution and application. British Journal of Dermatology, 159(5), 997-1035. link ↗
How to cite this page
ScholarGate. (2026, June 3). Dermatology Life Quality Index. ScholarGate. https://scholargate.app/en/health-outcomes/dlqi
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
Compare side by side →